- Brings over 20-year global commercialization experience in
oncology with leading biopharmaceutical companies Gilead
Sciences and Bristol Myers Squibb, including leadership of multiple
commercial launches for products including Trodelvy® and
Opdivo®
SOUTH
SAN FRANCISCO, Calif., Nov. 18,
2024 /PRNewswire/ -- IDEAYA Biosciences, Inc.
(Nasdaq:IDYA), a precision medicine oncology company committed to
the discovery and development of targeted therapeutics, today
announced the appointment of Stu
Dorman as Chief Commercial Officer. Mr. Dorman has a track
record of commercial success in numerous specialty disease areas
with over 20 years of oncology and hematology experience.
"We are thrilled to welcome Stu as IDEAYA makes continued
enrollment progress in the potential registrational trial for
darovasertib in first-line HLA-A2(-) MUM, and the potential
indication expansion opportunity in neoadjuvant UM. Stu has
extensive commercial experience in global product
commercialization, product launches, sales and market access. Most
importantly, Stu's proven track record in maximizing the commercial
opportunity for several global blockbuster cancer treatments, such
as Trodelvy® and Opdivo®, makes him an ideal
fit to lead our commercial organization," said Yujiro S. Hata, President and Chief Executive
Officer of IDEAYA Biosciences.
"I am delighted to join IDEAYA to build an industry-leading
commercial organization that is well positioned to deliver
potential first-in-class precision medicine oncology therapies that
can improve the lives of cancer patients worldwide. I look forward
to leveraging my extensive commercial oncology experience as
darovasertib continues to make progress in the potential
registrational trial in first-line HLA-A2(-) MUM and targeted Phase
3 start in neoadjuvant UM, and as the broader clinical
pipeline advances, including IDE397 in MTAP-deletion non-small cell
lung cancer and urothelial cancer," commented Mr. Dorman.
Prior to joining IDEAYA, Mr. Dorman was the Vice President, U.S.
Oncology Business Unit Head at Gilead Sciences, where he
successfully built a leading oncology commercial organization with
over a billion in global annual sales, and successfully launched
Trodelvy in multiple indications. Prior to that, Mr. Dorman held
positions of increasing responsibility at Bristol Myers Squibb
(BMS) where he built, led, and transformed global sales and
marketing teams to deliver outstanding commercial execution
including multiple successful launches. He concluded his 14-year
tenure at BMS as Vice President, Worldwide Oncology
Commercialization in its diverse oncology portfolio, including
leading commercial strategy for Opdivo, Yervoy and Abraxane. He
received his M.B.A. from Standford Graduate School of Business and
his A.B. in Economics with Honors from Harvard
University.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the
discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's approach
integrates capabilities in identifying and validating translational
biomarkers with drug discovery to select patient populations most
likely to benefit from its targeted therapies. IDEAYA is applying
its research and drug discovery capabilities to synthetic lethality
– which represents an emerging class of precision medicine
targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to the Company's potential commercialization of
darovasertib and other product candidates in IDEAYA's clinical
pipeline and Mr. Dorman's impact on IDEAYA's business. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's Annual
Report on Form 10-K dated February 20, 2024 and any
current and periodic reports filed with the U.S. Securities and
Exchange Commission.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
SVP, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-appoints-stu-dorman-as-chief-commercial-officer-302307574.html
SOURCE IDEAYA Biosciences, Inc.